Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib

Next Previous
Trial Profile

An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niraparib (Primary)
  • Indications Breast cancer; Male breast cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 28 Nov 2023 This trial has been completed in Denmark, according to European Clinical Trials Database record.
  • 28 Nov 2023 This trial has been completed in Denmark, according to European Clinical Trials Database record.
  • 20 Jul 2022 Planned End Date changed from 8 Apr 2026 to 13 Nov 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top